Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

CEO Albert Bourla highlighted Pfizer's strong execution in 2024, emphasizing the successful integration of Seagen, which has positioned Pfizer as a leading oncology company. He noted, "We met or ...

Demand for Pfizer’s COVID-19 products and oncology drugs could fall short of expectations, and risks related to key product sales, pricing pressure, and pipeline developments persist.

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...

Pfizer is laying down new pieces for its leadership team structure, selecting Jeffrey Legos, Ph.D., to replace interim Chief Oncology Officer Roger Dansey, M.D. As head of oncology, Legos will ...

Pfizer names oncology head Chris Boshoff as R&D chief. By Sriparna Roy and Michael Erman. November 20, 2024 4:05 PM UTC Updated November 20, 2024 The Pfizer logo is pictured on ...

Pfizer has partnered with Syapse to use the San Francisco-based software company's data-sharing network and insights platform to advance the development of precision cancer treatments.

Pfizer reported Q4 2024 revenue of $17.8 billion, with $13.7 billion from non-COVID products, reflecting 11% operational year-over-year growth. Key growth drivers included the Vyndaqel family ...